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creativecommons.org/licenses/by-nc-nd/Abstract Metastatic colorectal carcinoma (mCRC) is a heterogeneous disease with differing
outcomes and clinical responses and poor prognosis. CRCs can be characterised by their pri-
mary tumour location within the colon. The left-sided colon, derived from the hindgut, in-
cludes the distal third of the transverse colon, splenic flexure, descending colon, sigmoid
colon and rectum. The right-sided colon, derived from the midgut, includes the proximal
two-thirds of the transverse colon, ascending colon and caecum. Sometimes, the rectum is
described separately, despite originating from the hindgut, and in many clinical series, the
left-sided colon includes only tumours within and distal to the splenic flexure. Differences
in the microbiome, clinical characteristics and chromosomal and molecular characteristics
have been reported between the right and left side of the colon, regardless of how this is
defined. There is now strong evidence from clinical studies in patients with mCRC for the
prognostic effect of primary tumour location. The impact of primary colonic tumour location
on response to treatment is now under investigation in a large number of clinical studies in
patients with mCRC.
In this review, we summarise the microbiome, clinical, chromosomal and molecular differ-
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In Europe, colorectal carcinoma (CRC) is the second
most commonly diagnosed cancer and a leading cause of
death [1,2]. Metastatic CRC (mCRC) is a heterogeneous
disease with differing outcomes and clinical responses.
Over the past 20 years, the clinical outcome for these
patients has greatly improved because of the expansion
in available systemic therapies and ablative techniques,
in addition to improved diagnosis and referral for sur-
gery [3]. However, prognosis for mCRC patients re-
mains poor [3]. Clinical studies, to date, have reported a
median overall survival (OS) of approximately 24e30
months, achieved with the aid of multiple lines of
treatment followed by best supportive care (BSC) [3].
CRCs can be characterised by their primary tumour
location within the colon and rectum [4]. Historically,
publications have defined CRCs within three compart-
ments of the gut: distal colon, proximal colon and rectum
[4e6]. Right-sided colon carcinomas (RCCs) are located
within the colon derived from the embryologic midgut,
which encompasses the proximal two-thirds of the
transverse colon, ascending colon and caecum (Fig. 1).
Left-sided colon carcinomas (LCCs) lie within the colon
derived from the embryologic hindgut, which includes the
distal third of the transverse colon, splenic flexure,
descending colon, sigmoid colon and rectum (Fig. 1). It
should be noted that the rectum is sometimes described
separately although it embryonically belongs to the
hindgut. Most clinical series have used a slightly different
definition, with any tumour proximal to the splenic
flexure considered a right-sided primary and any tumourst commonly used definition
colon and rectum.from the splenic flexure and distally (including the
rectum) considered a left-sided primary. With this defi-
nition, at least 63% of patients with CRC have LCC [7].
Prognostic biomarkers predict a likely disease
outcome, independent of the treatment received. Strong
evidence for the prognostic effect of primary tumour
location is available from clinical studies in patients with
mCRC [8e13]. Predictive biomarkers may identify pa-
tients who are most likely to benefit from a certain
treatment. Clinical studies in patients with mCRC are
now evaluating the impact of primary colonic tumour
location on response to treatment, with a particular
focus on biologics [12e17].
Here, we present an overview of the microbiome and
molecular differences associated with the primary loca-
tion of CRC, and we discuss the prognostic and pre-
dictive impact of primary tumour location on clinical
outcome for these patients.
2. Embryology of the midgut and hindgut
During gastrulation, the right (midgut) and left (hind-
gut) side of the gut develop from the endoderm and
extend along the length of the embryo from the bucco-
pharyngeal membrane to the cloacal membrane [18].
The midgut gives rise to the duodenum distal to the
ampulla, the entire small bowel, the caecum, appendix,
ascending colon and the proximal two-thirds of the
transverse colon [19].
The distal third of the transverse colon, splenic
flexure, descending colon and sigmoid rectum and the
upper part of the anal canal originate from the hindgut
[19]. The most distal portion of the hindgut enters into
the posterior region of the cloaca, called the primitive
anorectal canal, from which the anal region is derived.
Because both the right and left side of the colon derive
from the endoderm [18], embryology does not appear to
be the major source of the differences observed in the
prognosis of CRC. Distinct gene expression differences,
reflecting the midgut and hindgut differences, have been
reported between the right and left side of the normal
colon, as described later in this article [11,20e22].
3. Microbiome differences between the normal gut and CRC
Limited data are available on the differences of the
microbiome within healthy colon tissue, and there are
currently no large analyses published on the distinct dif-
ferences between the transverse and descending colon.
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proximal colon to the rectum has been reported [23]. The
microbiome is believed to play an important part in the
formation of CRC. Bacterial phylotypes are known to
vary depending on the primary tumour location (Table 1)
[23e25]: RCCs have a relatively higher abundance of
Prevotella, Pyramido-bacterium, Selenomonas and Pep-
tostreptococcus than LCC, which have a higher preva-
lence of Fusobacterium, EscherichiaeShigella and
Leptotrichia compared with RCC [23]. A significantly
higher incidence of Escherichia coli phylogroup B2 has
been detected in mucosal biopsies from patients with
RCC compared to those with LCC [24], and a higher risk
of Helicobacter pylori infection was reported in patients
with LCC compared to those with RCC [25]. A lower
abundance of Gram-positive, fibre-fermenting clostridia
and an increased prevalence of Gram-negative, pro-in-
flammatory bacteria (i.e. E. coli phylogroup B2) has been
reported in patients with CRC compared with controls
[24,26].
Dense bacterial aggregates, or biofilms, are located
within the normal gut and are associated with decreased
E-cadherin, enhanced interleukin-6 (IL-6) and signalTable 1
Microbiome differences between RCC and LCC.
RCC
 Higher abundance of Prevotella, Pyramido-bacterium,
Selenomonas and Peptostreptococcus [23]
 Higher incidence of Escherichia coli phylogroup B2 [24]
LCC, left-sided colon carcinoma; RCC, right-sided colon carcinoma.
Table 2
Chromosomal and molecular characteristics of RCC and LCC.
RCC LCC
 High MSI and CIMP [9,11]
 Hypermutation state
 KRAS mutations [9,11]
 BRAF mutations [9,11]
 TGFbR2 mutations [33]
 PI3KCA mutations [33]
 Chrom
 Dele
gain
 Aneup
 Freque
 TP53
 APC
 KRA
 Overex
 EGF
 High
 High
 COX
 Distribution of CMS subtypes [20]
 CMS1 e 31%
 CMS2 e 26%
 CMS3 e 19%
 CMS4 e 24%
 Distrib
 CMS
 CMS
 CMS
 CMS
AREG, amphiregulin; CIMP, CpG island methylator phenotype; CMS, co
EREG, epiregulin; LCC, left-sided colon carcinoma; MSI, microsatellit
endothelial growth factor 1.transducer and activator of transcription 3 (STAT3)
activation and increased epithelial cell proliferation [27].
Biofilms can invade the mucus layer of the colon and
may be pathogenic when they make direct contact with
the mucosal epithelial cells. Invasive poly-microbial
bacterial biofilms have been detected on the majority
of RCCs, but on only a small percentage of LCC [27].
It remains unclear whether the changed mucosa
following the development of CRC attracts different
bacteria or if different bacteria have an ability to destroy
the mucosa, which then leads to CRC. Both mechanisms
have been postulated. Prevotella, Pyramido-bacterium,
Selenomonas and Peptostreptococcus were identified in
relatively higher abundance in proximal tumours
compared with distal tumours [23]. Conversely, Fuso-
bacterium, Escherichia-Shigella and Leptotrichia were
relatively abundant in distal colorectal tumours
compared with proximal tumours [23]. Recently pub-
lished data show that CRC-associated bacterial clusters
are differentially correlated with mucosal gene expres-
sion profiles [28]. Some clusters are partly associated
with the expression of pro-inflammatory genes in the
mucosa, which may result in CRC in future [28].LCC
 Higher prevalence of Fusobacterium, Escherichia-Shigella
and Leptotrichia [23]
 Higher risk of Helicobacter pylori infection [25]
osomal aberrations
tion of 8p, 17p (including TP53), 18p (including SMAD4),
of chromosome 7, 8q (including MYC ), 20q, loss of 18q [33]
loidy [50]
ntly mutated genes: [33]
S
pression:
R and HER2 gain [22,36]
EGFR ligand expression (EREG and AREG expression) [22,35]
VEGF-1 mRNA expression [38]
-2 [39]
ution of CMS subtypes [20]
1 e 7%
2 e 56%
3 e 10%
4 e 27%
nsensus molecular subtype; EGFR, epidermal growth factor receptor;
e instability; RCC, right-sided colon carcinoma; VEGF-1, vascular
Fig. 2. A) Molecular characteristics of CRC [32] [Reproduced from Gut 2012, ‘Assessment of colorectal cancer molecular features along
bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum’, Yamauchi M et al, 61, 847e54,
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primary tumour location
A similar or greater proportion of patients with RCC
are female, and the median age of patients with RCC at
diagnosis is higher compared to patients with LCC
[7,8,11]. RCCs are more likely to have high-grade his-
tology and a more advanced tumour stage at initial
presentation compared with LCC [7,11,29]. A low-fibre
diet, smoking and alcohol excess tend to be associated
with LCC [30].
Metastatic spread also differs depending on the pri-
mary location of the CRC. RCC more often metastasise
to the peritoneum, and a greater proportion of LCC will
metastasise to liver and lung [22].5. Chromosomal and molecular differences according to
primary tumour location
A number of chromosomal and molecular differences
have been reported between RCC and LCC (Table 2).
Chromosomal instability has been detected in approxi-
mately 75% of LCC and 30% of RCC [30].
Hypermutation is more prevalent in RCC compared
with LCC [22]. RCC have been shown to be associated
with an increase in RAS and phosphoinositide 3-kinase
pathway mutations [31], CpG island methylator
phenotype (CIMP)ehigh and microsatellite insta-
bilityehigh subtypes (Fig. 2A) and BRAF mutations
(Fig. 2B) [22,32]. The frequency of KRAS/BRAF mu-
tations has been noted to progressively decrease from
the caecum to sigmoid colon (Fig. 2B) [11]. A higher
expression of TGFbR2 mutations also occurs within the
RCC compared with the LCC [33].
Mutations in the APC, KRAS, SMAD4 and TP53
genes occur more often in LCC compared with RCC [34].
In addition to the increased chromosomal instability of
LCC, these tumours have also been associated with more
frequent overexpression of the epidermal growth factor
receptor (EGFR) ligands, epiregulin (EREG) and
amphiregulin (AREG) and amplification of EGFR and
human epidermal growth factor receptor 2 (HER2)
[22,35,36]. High AREG expression is inversely associated
with BRAF mutation and CIMP-high status [35].
Hypermethylation and suppression of EREGandAREG
expressions have been demonstrated to be strongly
associated with RCC and CIMP-high status [37].
The predominant angiogenic factor, vascular endo-
thelial growth factor (VEGF-1), plays a key role in the
progression of CRC. The expression of VEGF-1 hascopyright 2017 with permission from BMJ Publishing Group Ltd.] a
tumour location [11] [Reproduced from Clin Cancer Res 2015, ‘Analys
carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Allia
permission from AACR]. CIMP, CpG island methylator phenotype;
microsatellite stability.been reported to be significantly higher in LCC
compared with RCC [38]. Similarly, a more frequent
expression of cyclooxygenase-2 (COX-2), which also has
a role in angiogenesis, was identified in LCC compared
with RCC [39].
The CRC Subtyping Consortium has defined four
molecular subtypes of CRC (consensus molecular sub-
types [CMS] 1e4), based on six published gene expres-
sionebased CRC subtyping algorithms and the reported
differences in clinical, chromosomal and molecular
characteristics between the primary tumour locations
[20]. RCC are predominantly CMS1 (microsatellite
instability and strong immune activation) and LCC are
mostly CMS2 (canonical) (Table 2) [37].6. Prognostic effects of primary tumour location on
clinical outcome
The different clinical and biological profiles of RCC and
LCC suggested that primary tumour location might
have a potential impact on the prognosis of these pa-
tients and strong evidence is now available to confirm
this (Table 3) [8e13]. Although tumour localisation is
not included within the European Society for Medical
Oncology consensus guidelines for the treatment of pa-
tients with mCRC, it is mentioned in the current Na-
tional Comprehensive Cancer Network (NCCN)
guidelines [3,40].
The prognostic effect of primary tumour localisation
on clinical outcome was first reported in 1990 [4]. In a
randomised phase III study (FIRE-1), patients with
RCC had a significantly shorter progression-free sur-
vival (PFS) and OS compared with those who had LCC
[15] (Table 3). This study was limited, however, by its
small sample size. Further conclusive evidence was
provided by multivariable analysis of a prospective
pharmacogenetic study (PROVETTA) and two rando-
mised phase III studies (AVF2107g and NO16966) of
over 2000 patients with previously untreated mCRC:
superior OS and PFS were observed in patients with
LCC compared with RCC across all three studies [8].
RCC was therefore confirmed as a negative prognostic
variable. A stepwise improvement in OS from the RCC
to LCC has been demonstrated by subgroup analysis of
OS and time-to-recurrence (TTR) by primary tumour
location (Fig. 3) [11]. Caecal tumours had the lowest
TTR and OS, and sigmoid colonic tumours had the
highest TTR and OS.
Recently, a meta-analysis of 66 clinical studies has
been published, comparing the OS of RCC versus LCCnd B) frequency of molecular alterations, according to primary
is of molecular markers by anatomic tumor site in Stage III colon
nce)’ Sinicrope FA et al, 21(23), 5294-5304, copyright 2017 with
CRC, colorectal carcinoma; MSI, microsatellite instability; MSS,
Table 3
Summary of the prognostic impact of CRC location on clinical outcomes.
Study details Regimens Median PFS (RCC versus
LCC, months)
HR (95% CI), P value
Median OS (RCC versus
LCC, months)
HR (95% CI), P value
Prospective, pharmacogenetics study
PROVETTAa [8] (n Z 200) FOLFIRI þ BEV 9.9 versus 12.1
0.52 (0.36e0.75), <0.001a
24.8 versus 42.0
0.44 (0.28e0.70), <0.001a
PROVETTAa:
non-mucinous/BRAF
WT subgroup [8] (n Z 155)
FOLFIRI þ BEV 10.0 versus 13.0
0.54 (0.34e0.84), 0.01a
28.8 versus 47.6
0.52 (0.30e0.93), 0.02a
Retrospective studies
Chinese 2-center study
[17] (n Z 110)
CT þ CET 5.6 versus 9.1
ND, 0.244
25.1 versus 28.9
ND, 0.512
Chinese 2-centre study
[17] (n Z 117)
CT 5.7 versus 6.2
ND, 0.160
19.8 versus 20.1
ND, 0.593
Taiwanese single-centre
caseecontrol
study [51] (n Z 121)
FOLFOX or FOLFIRI þ CET or BEV 5.8 versus 11.8
ND, <0.001a
15.7 versus 27.7
ND, 0.008a
Randomised, phase II studies
AIO KRK-0104 [42] (n Z 146) CET þ CAPIRI or CET þ CAPOX 5.2 versus 7.8
0.67 (0.47e0.95), 0.02
14.8 versus 26.3
0.63 (0.43e0.92), 0.016
AIO KRK-0104: KRAS codon
12/13 WT [42] (n Z 95)
CET þ CAPIRI or CET þ CAPOX 4.6 versus 8.4
0.54 (0.34e0.85), 0.007a
13.0 versus 29.0
0.42 (0.25e0.67), <0.001a
AIO KRK-0104: KRAS codon
12/13 MT [42] (n Z 51)
CET þ CAPIRI or CET þ CAPOX 7.5 versus 5.8
1.01 (0.56e1.82), 0.96
18.9 versus 19.7
1.3 (0.68e2.34), 0.46
PEAKb [14] (n Z 65) Pmab þ FOLFOX 10.3 versus 14.6
ND
22.5 versus 43.4
ND
PEAKb [14] (n Z 66) BEV þ FOLFOX 12.6 versus 11.5
ND
23.3 versus 32.0
ND
Randomised, phase III studies
FIRE-1 [15] (n Z 423) FUFIRI or mIROX 6.0 versus 8.2
0.75 (0.59e0.87), 0.024a
13.6 versus 21.8
0.65 (0.50e0.84), 0.001a
FIRE-1 [15] (n Z 209) mIROX 6.0 versus 7.8
0.84 (0.59e1.21), 0.35
14.0 versus 20.4
0.74 (0.51e1.08), 0.12
FIRE-1 [15] (n Z 214) FUFIRI 6.0 versus 8.7
0.66 (0.46e0.94), 0.02a
12.5 versus 25.0
0.55 (0.39e0.79), 0.001a
AVF2017gc [8] (n Z 559) CT  BEV 7.1 versus 8.5
0.68 (0.55e0.83), <0.001a
14.6 versus 20.4
0.55 (0.43e0.70), <0.001a
AVF2017gc [8] (n Z 277) CT þ BEV 8.7 versus 11.1
0.62 (0.45e0.85), 0.01a
15.9 versus 24.2
0.49 (0.34e0.70), <0.001a
AVF2017gc [8] (n Z 282) CT 5.4 versus 8.0
0.72 (0.55e0.96), 0.02a
13.6 versus 18.0
0.62 (0.44e0.86), 0.01a
NCIC CO.17d: re-analysis
[48] (n Z 199)
BSC ND
1.07 (0.79e1.44), 0.67
ND
0.96 (0.70e1.31), 0.78
NO16966e [8] (n Z 1268) FOLFOX4 or XELOX or
FOLFOX4 þ BEV or XELOX þ BEV
7.6 versus 8.9
0.90 (0.79e1.03), 0.12
18.0 versus 23.0
0.71 (0.62e0.82), <0.001a
NO16966e [8] (n Z 441) FOLFOX4 þ BEV or XELOX þ BEV 8.6 versus 10.0
0.95 (0.76e1.19), 0.64
20.6 versus 24.7
0.78 (0.61e0.99), 0.04a
NO16966e [8] (n Z 827) FOLFOX4 or XELOX 7.0 versus 8.3
0.87 (0.74e1.03), 0.10
17.0 versus 22.0
0.67 (0.57e0.80), <0.001a
CALGB/SWOG 80405f:
KRAS WT [12] (n Z 1025)
CET þ CT or BEV þ CT 8.9 versus 11.5
1.25 (1.08e1.46), 0.002
19.4 versus 34.2
1.56 (1.32e1.84), <0.0001
CALGB/SWOG 80405f:
KRAS MT [12] (n Z 213)
CET þ CT or BEV þ CT ND 23.1 versus 30.3
1.28 (0.95e1.73), <0.0001
PRIMEg [14] (n Z 182) Pmab þ FOLFOX 8.9 versus 12.9 22.5 versus 32.5
PRIMEg [14] (n Z 180) FOLFOX 7.3 versus 9.3 21.5 versus 23.6
FIRE-3h: RAS exon 2 WT
[16] (n Z 195)
CET þ FOLFIRI 7.6 versus 10.7
2.0 (1.36e2.93), <0.001a
18.3 versus 38.3
2.84 (1.86e4.33), <0.001a
FIRE-3h: RAS exon 2 WT
[16] (n Z 199)
BEV þ FOLFIRI 9.0 versus 10.7
1.38 (0.99e1.94), 0.06
23.0 versus 28.0
1.48 (1.02e2.16), 0.04
CRYSTALi: RAS WT
[16] (n Z 175)
FOLFIRI þ CET 8.1 versus 12.0
1.77 (1.08e2.91), 0.02
18.5 versus 28.7
1.93 (1.24e2.99), 0.003
CRYSTALi: RAS WT
[16] (n Z 189)
FOLFIRI 7.1 versus 8.9
1.54 (0.96e2.46), 0.07
15.0 versus 21.7
1.35 (0.93e1.97), 0.11
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Table 3 (continued )
Study details Regimens Median PFS (RCC versus
LCC, months)
HR (95% CI), P value
Median OS (RCC versus
LCC, months)
HR (95% CI), P value
Registry
Australian TRACC registry [13]
(n Z 926)
CT  BEV 7.6 versus 10.2 (rectum 10.3)
ND, <0.0001a
18.2 versus 23.6 (rectum 26.2)
ND, 0.0007a
Clinicaltrials.gov identifiers: aNCT01363739; bNCT00819780; cNCT00109070; dNCT00079066; eNCT00069095; fNCT00265850; gNCT00364013;
hNCT00433927; iNCT00154102.
BEV, bevacizumab; BSC, best supportive care; CAPIRI, capecitabine, irinotecan; CAPOX, capecitabine, oxaliplatin; CET, cetuximab; CI,
confidence interval; CT, chemotherapy; FOLFOX, bolus 5-fluorouracil/leucovorin/oxaliplatin; FOLFIRI, bolus 5-fluorouracil/leucovorin/
irinotecan; FUFIRI, infusional 5-fluorouracil/leucovorin/irinotecan; HR, hazard ratio; LCC, left-sided colon carcinoma; mIROX, irinotecan,
oxaliplatin; MT, mutated; ND, not determined (not published in primary source cited); OS, overall survival; PFS, progression-free survival;
Pmab, panitumumab; RCC, right-sided colon carcinoma; WT, wild-type; XELOX, capecitabine, oxaliplatin.
a Statistically significantly different (P<0.05).
Fig. 3. Clinical outcome of patients with stage III CRC according to tumour localisation: A) overall survival and B) time-to-recurrence
[11] [Reproduced from Clin Cancer Res 2015, ‘Analysis of molecular markers by anatomic tumor site in Stage III colon carcinomas from
adjuvant chemotherapy trial NCCTG N0147 (Alliance)’ Sinicrope FA et al, 21(23), 5294-5304, copyright 2017 with permission from
AACR]. CI, confidence intervals; CRC, colorectal carcinoma; HR, hazard ratio; OS, overall survival; Ref., reference group; TTR, time-to-
response.
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CRC [41]. A pooled hazard ratio of 0.82 (P<0.001) was
reported in favour of LCC. Patients with LCC had a
20% reduction in the risk of death compared with RCC,
independent of ethnicity, disease stage and type of
study. This meta-analysis concluded that primary
tumour location should be established as a key criterion
for confirming OS outcomes in all stages of CRC.
Several studies have investigated the contribution of
mutational status (i.e. KRAS and BRAF ) and key
marker expression (i.e. HER2 and EGFR) to the impact
of primary tumour location on prognosis [11,12,35,42].
In patients with KRAS codon 12/13 wild-type (WT)
CRC, LCC were associated with a significantly longer
PFS and OS compared with RCC [42]. No impact of
primary tumour location on clinical outcomes was
observed in patients with KRAS-mutated (MT) mCRC
in this study. In the North Central Cancer TreatmentGroup (NCCTG) N0147 (Alliance) study, however,
KRAS-MT LCC was associated with poorer OS
compared with KRAS-MT RCC [11]. BRAF mutations
have been shown to be associated with poorer outcomes
for patients with mCRC than BRAF WT, and these are
more prevalent in RCC than LCC [11]. The current in-
ternational guidelines for the management of patients
with mCRC recognise the prognostic impact of muta-
tional status and recommend that patients are tested for
RAS and BRAF mutation status before establishing a
first-line treatment regimen [3,40].
However, RAS and BRAF mutational status are not
the only prognostic factors for patients with mCRC. In
a multivariant analysis of two randomised phase III
studies (CRYSTAL and FIRE-3), LCC and RCC were
highly prognostic for PFS and OS even when patients
with BRAF mutation were excluded [16]. In subgroup
analysis from two randomised phase III studies (FIRE-3
S. Stintzing et al. / European Journal of Cancer 84 (2017) 69e8076and TRIBE), IL-6 genetic variants were identified as a
prognostic factor for patients with mCRC treated with
first-line bevacizumab-based chemotherapy, depending
on primary tumour location [43].
To summarise, the primary tumour location is a
known prognostic factor for patients with CRC [8e13].
A meta-analysis from prospective and retrospective
clinical studies reporting OS data for LCC and RCC
mCRC concluded that patients with RCC had poorer
prognosis than those with LCC [41]. This appears to be
independent of the mutational spectrum within these
tumours [12,16].7. Predictive effects of primary tumour location on clinical
outcome
Given the differential expression of EGFR and of
EGFR ligands, and the differing incidence of KRAS
mutations between RCC and LCC, several studies have
investigated the predictive effect of primary tumour
location on clinical outcomes from treatment with
EGFR and VEGF inhibitors in patients with CRC
[12e17] (Table 4).
Post-hoc analysis of clinical studies suggests that
although anti-EGFR therapy provides clinical benefit to
patients with RAS WT mCRC, this benefit is not rele-
vant for patients with RCC [12,16,44]. In a subgroup
analysis by tumour location from the CALGB/SWOG
80405 study, prolonged OS and PFS were observed in
patients with LCC treated with either cetuximab or
bevacizumab plus 5-fluorouracil/leucovorin/irinotecan
(FOLFIRI) or 5-fluorouracil/leucovorin/oxaliplatin
(FOLFOX), however outcomes were poorer in patients
with RCC who were treated with cetuximab plus
FOLFIRI or FOLFOX [12]. In the FIRE-3 and
CRYSTAL randomised phase III studies of patients
with RAS WT CRC, differential treatment effects were
observed between primary tumour locations [16]. Pa-
tients who received cetuximab plus FOLFIRI in the
CRYSTAL study had significantly improved outcomes
compared with those who received FOLFIRI alone.
This benefit was greater in patients with LCC compared
with those with RCC [16]. In FIRE-3, patients with
LCC who received cetuximab plus FOLFIRI as first-line
therapy had a significantly longer OS than those who
received bevacizumab plus FOLFIRI [16]. No signifi-
cant difference in clinical outcomes was observed be-
tween these treatment groups for patients with RCC.
This may be driven by LCC having a higher EGFR
expression than RCC, differences in EGFR ligand
expression or other as yet unidentified factors [22]. The
NCCN guidelines recommend the use of anti-EGFR
substances for the treatment of RASWT LCC only [40].
Similar data have been presented for the use of
panitumumab in first-line mCRC [14]. A retrospective
analysis of the PRIME study showed a significantsurvival benefit for patients with LCC treated with
FOLFOX plus panitumumab when compared with
FOLFOX alone. In contrast, no benefit was associated
with FOLFOX plus panitumumab in patients with
RCC. Since this is in accordance with the cetuximab
data, it appears to be a class effect. A meta-analysis
comparing clinical outcome data from multiple clinical
studies according to primary tumour location has
already been published [45].
In the prospective PROVETTA clinical study of pa-
tients with CRC who received bevacizumab plus
chemotherapy, VEGF expression was similar across
primary tumour locations [8]. Efficacy results from the
PROVETTA, AVF2107g and NO16966 studies
confirmed that first-line bevacizumab in combination
with chemotherapy improves clinical outcomes for pa-
tients with CRC, irrespective of primary tumour loca-
tion [8]. Several other clinical studies have also provided
evidence that tumour location does not appear to be
predictive of benefit from bevacizumab treatment in
patients with CRC [12,13,46,47].
Limited data are currently available on the predictive
impact of primary tumour location on clinical outcome
following second-line or later treatment (Table 5). In a re-
analysis of the phase III NCIC CO-17 study of patients
with KRAS WT mCRC who had failed standard chemo-
therapy, those with LCC who received cetuximab experi-
enced a significantly improved PFS compared with those
treated with BSC [48]. This clinical benefit was not
observed in patients with RCC. Similarly, in preliminary
efficacy data from another phase III study (Study
20050181), where patients with mCRC received second-
line panitumumab plus FOLFIRI, improved clinical out-
comes were observed in patients with LCC compared with
RCC [14]. Although these findings suggest that tumour
location may strongly predict clinical benefit with cetux-
imab or panitumumab, these studies were limited by their
low sample size and a lack of stratification byBRAF status
in some studies. Retrospective analysis from the phase III
FIRE-3 study of patients withKRASWTmCRC reported
a significantly greater efficacy of second-line therapy in
patients with LCC compared with RCC [44]. This differ-
ence wasmore evident for patients with LCCwho received
second-line cetuximab compared with those who received
second-line bevacizumab. These observations indicate that
efficacy of second-line therapy is associated with primary
tumour location.
HER2/neu has been identified as a predictive
biomarker in mCRC [36]. HER2/neu-amplifications
have been shown to be more prevalent in LCC than in
RCC. This suggests that patients with LCC may benefit
more from a HER2-directed therapy, including agents
such as trastuzumab [36]. A recent study has reported
similar clinical outcomes for patients with HER2-
amplified or HER2-non-amplified RAS/BRAF WT
CRC on first-line therapy without anti-EGFR anti-
bodies [49]. Patients with HER2-amplified RAS/BRAF
Table 4
Summary of the predictive impact of CRC location on clinical outcomes following first-line therapy.
Study details PFS by treatment arm (months)
HR (95% CI), P value
OS by treatment arm (months)
HR (95% CI), P value
RCC LCC RCC LCC
Retrospective study
Chinese 2-centre study [17]
(n Z 227)
CT (5.7) versus CT þ CET (5.6)
ND, 0.904
CT (6.2) versus CT þ CET (9.1)
ND, 0.002a
CT (19.8) versus CT þ CET (25.1)
ND, 0.553
CT (20.1) versus CT þ CET (28.9)
ND, 0.036a
Randomised, phase II study
PEAKa [14] (n Z 133) Pmab þ FOLFOX (10.3) versus
BEV þ FOLFOX (12.6)
0.88 (0.39e2.02), ND
Pmab þ FOLFOX (14.6) versus
BEV þ FOLFOX (11.5)
0.67 (0.44e1.02), ND
Pmab þ FOLFOX (22.5) versus
BEV þ FOLFOX (23.3)
0.63 (0.26e1.54), ND
Pmab þ FOLFOX (43.4) versus
BEV þ FOLFOX (32.0)
0.77 (0.46e1.28), ND
Randomised, phase III studies
FIRE-1 [15] (n Z 423) FUFIRI (6.0) versus mIROX (6.0)
0.94 (0.60e1.489), 0.79
FUFIRI (8.7) versus mIROX (7.8)
1.17 (0.94e1.46), 0.17
FUFIRI (12.5) versus
mIROX (14.5)
0.90 (0.57e1.43), 0.65
FUFIRI (25.0) versus mIROX (20.4)
1.17 (0.93e1.47), 0.19
CALGB/SWOG 8040b:
KRAS WT [12] (n Z 1137)
CET (7.7) versus BEV (9.5)
ND, ND ‘similar to OS’
CET (12.0) versus BEV (11.1)
ND, ND ‘similar to OS’
CET (16.4) versus BEV (24.5)
ND, 0.03a (CET versus BEV
superiority log rank)
CET (37.5) versus BEV (32.1)
ND, 0.04a (CET versus BEV
superiority log rank)
PRIMEc [14] (n Z 362) Pmab þ FOLFOX (8.9) versus
FOLFOX (7.3)
0.71 (0.4e1.27), ND
Pmab þ FOLFOX (12.9) versus
FOLFOX (9.3)
0.69 (0.54e0.88), ND
Pmab þ FOLFOX (22.5)
versus FOLFOX (21.5)
0.94 (0.53e1.67), ND
Pmab þ FOLFOX (32.5) versus
FOLFOX (23.6)
0.67 (0.56e0.86), ND
FIRE-3d: RAS exon 2 WT
[16] (n Z 394)
FOLFIRI þ CET (7.6) versus
FOLFIRI þ BEV (9.0)
1.44 (0.92e2.26), 0.11
FOLFIRI þ CET (10.7) versus
FOLFIRI þ BEV (10.7)
0.90 (0.71e1.14), 0.38
FOLFIRI þ CET (18.3)
versus FOLFIRI þ BEV (23.0)
1.31 (0.81e2.11), 0.28
FOLFIRI þ CET (38.3) versus
FOLFIRI þ BEV (28.0)
0.63 (0.48e0.85), 0.002
CRYSTALe: RAS WT
[16] (n Z 364)
FOLFIRI þ CET (8.1) versus
FOLFIRI (7.1)
0.87 (0.47e1.62), 0.66
FOLFIRI þ CET (12.0) versus
FOLFIRI (8.9)
0.50 (0.34e0.72), <0.001
FOLFIRI þ CET (18.5)
versus FOLFIRI (15.0)
1.08 (0.65e1.81), 0.76
FOLFIRI þ CET (28.7) versus
FOLFIRI (21.7)
0.65 (0.50e0.86), 0.002
Registry
TRACC Australian Registry
[13] (n Z 926)
CT (4.9) versus CT þ BEV (8.54)
0.46 (0.36e0.60), <0.001a
CT (7.5; rectum: 7.1) versus CT þ BEV
(10.5; rectum 11.3)
0.71 (0.56e0.91)
(rectum 0.64 [0.50e0.84]), 0.006a
(rectum 0.001a)
ND
ND
ND
ND
Clinicaltrials.gov identifiers: aNCT00819780; bNCT00265850; cNCT00364013; dNCT00433927; eNCT00154102.
BEV, bevacizumab; CET, cetuximab; CI, confidence interval; CT, chemotherapy; FOLFOX, bolus 5-fluorouracil/leucovorin/oxaliplatin; FOLFIRI, bolus 5-fluorouracil/leucovorin/irinotecan; FUFIRI,
infusional 5-fluorouracil/leucovorin/irinotecan; HR, hazard ratio; LCC, left-sided colon carcinoma; mIROX, irinotecan plus oxaliplatin; ND, not determined (not published in primary source cited);
OS, overall survival; PFS, progression-free survival; Pmab, panitumumab; RCC, right-sided colon carcinoma.
a Statistically significantly different (P<0.05).
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Table 5
Summary of the predictive impact of CRC location on clinical outcomes following second-line therapy.
Study details PFS by treatment arm (months)
HR (95% CI), P value
OS by treatment
arm (months)
HR (95% CI), P value
RCC LCC RCC LCC
Retrospective study
Chinese 2-centre study
[17] (n Z 189)
CT (4.2) versus
CT þ CET (3.3)
ND, 0.761
CT (3.5) versus
CT þ CET (4.9)
ND, 0.064
CT (13.0) versus
CT þ CET (13.4)
ND, 0.652
CT (12.4) versus
CT þ CET (17.1)
ND, 0.047a
Randomised, phase III studies
NCIC CO.17a:
re-analysis
[48] (n Z 399)
CET (1.8) versus
BSC (1.8)
0.93 (0.66e1.29), 0.64
CET (3.6) versus BSC (1.8)
0.53 (0.41e0.69), <0.0001a
CET (4.8) versus
BSC (4.5)
1.00 (0.70e1.43), 1.00
CET (6.8) versus
BSC (4.2)
0.60 (0.46e0.80), 0.0003a
20050181b [14]
(n Z 335)
Pmab þ FOLFIRI (6.8)
versus FOLFIRI (3.7)
0.62 (0.34e1.13), ND
Pmab þ FOLFIRI (8.0)
versus FOLFIRI (6.6)
0.89 (0.69e1.13), ND
Pmab þ FOLFIRI (11.9)
versus FOLFIRI (10.9)
0.84 (0.46e1.54), ND
Pmab þ FOLFIRI (20.1)
versus FOLFIRI (16.9)
0.97 (0.76e1.26), ND
FIRE-3c: RAS
exon 2 WT [44]
(n Z 411)
FOLFIRI þ CET (4.0)
versus FOLFIRI þ
BEV (3.3)
1.09 (0.62e1.90)
FOLFIRI þ CET (7.3)
versus FOLFIRI þ BEV (5.3)
0.61 (0.44e0.84), 0.002
Clinicaltrials.gov identifiers: aNCT00819780; bNCT00079066; cNCT00433927.
BSC, best supportive care; CET, cetuximab; CI, confidence interval; FOLFIRI, bolus 5-fluorouracil/leucovorin/irinotecan; HR, hazard ratio; LCC,
left-sided colon carcinoma; ND, not determined (not published in primary source cited); OS, overall survival; PFS, progression-free survival; Pmab,
panitumumab; RCC, right-sided colon carcinoma.
a Statistically significantly different (P<0.05).
S. Stintzing et al. / European Journal of Cancer 84 (2017) 69e8078WT CRC who received anti-EGFR antibodies after
first-line therapy had a significantly shorter PFS
compared to those with HER2-non-amplified CRC.
HER2 amplification, therefore, appears to be a predic-
tive biomarker for reduced benefit from anti-EGFR
antibody therapy and potential benefit from HER2-
targeted therapy (i.e. trastuzumab and lapatinib).
Primary tumour location appears, therefore, to have
a predictive effect on first- [12,14,16] and second-line
[14,44,48] anti-EGFR treatment and treatment in the
chemo-refractory setting [48]. Primary tumour location
does not appear to be predictive of clinical benefit from
anti-VEGF treatment [8,12,13,46,47].
8. Conclusions
Distinct subsets of mCRC can be defined based on the
location of the primary tumour. Patients with RCC and
LCC differ in their microbiome, clinical characteristics,
molecular profiling, clinical outcome and response to
treatment. The driver(s) and reason(s) for these differ-
ences remain unknown.
Based on current knowledge, and until the use of
anti-EGFR antibodies has been defined for each mo-
lecular subgroup of mCRC, we suggest that patients
with RAS WT RCC may benefit more from initial
treatment with bevacizumab in combination with
chemotherapy and those with LCC should receive first-
line treatment with anti-EGFR therapies and chemo-
therapy. Currently, data on RAS-MT LCC versus RCC
are limited; therefore, the prognostic and predictive
value of the primary tumour site within the RAS MTpopulation still requires evaluation. In addition, further
investigations are required to determine if the primary
tumour location and type of chemotherapy backbone
used (i.e. oxaliplatin-based [XELOX or FOLFOX] or
irinotecan-based [FOLFIRI or single-agent irinotecan])
are associated with different efficacies. Primary tumour
location should not only be a critical stratification factor
for clinical trials but should also be considered for the
translational workup of clinical trials and the retro-
spective analyses of prognostic and predictive markers.Conflict of interest statement
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